Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation

Internal Medicine

Volumn 51, Issue 6, 2012, Pages 659-661

  Tanaka, Kosuke ^a   Hata, Akito ^a   Kida, Yoko ^b   Kaji, Reiko ^a   Fujita, Shiro ^a   Katakami, Nobuyuki ^a   Imai, Yukihiro ^c  

^a INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^b KOBE CITY MEDICAL CENTER WEST HOSPITAL   (Japan)

^c KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

EGFR mutation; Gefitinib; Performance status; Squamous cell carcinoma

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR; GEFITINIB;

ADULT; ARTICLE; ATELECTASIS; BONE METASTASIS; BRONCHUS OBSTRUCTION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DRUG WITHDRAWAL; DYSPNEA; EMPYEMA; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; PARESTHESIA; POSITRON EMISSION TOMOGRAPHY; RESPIRATORY FAILURE; SMOKING; SQUAMOUS CELL CARCINOMA; THORAX RADIOGRAPHY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FATAL OUTCOME; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PALLIATIVE CARE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEVERITY OF ILLNESS INDEX; SMOKING; TAXOIDS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84863268470     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.6386     Document Type: Article

References (10)

1. Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98, 2002.
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353: 123-132, 2005.
3. Inoue A, Kobayashi K, Usui K, et al. North East Japan Gefitinib Study Group. First-line gefitinib for patients with advanced nonsmall cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27: 1394-1400, 2009.
4. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 22: 330-353, 2004.
5. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005.
6. Toyooka S, Takano T, Kosaka T, et al. Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. Cancer Sci 99: 303-308, 2008.
7. Travis W, Rekhtman N, Riley G, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 5: 411-414, 2010.
8. Park SH, Ha SY, Lee JI, et al. Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung. J Korean Med Sci 24: 448-452, 2009.
9. Shukuya T, Takahashi T, Kaira R, et al. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci 102: 1032-1037, 2011.
10. Sakurada A, Lara-Guerra H, Liu N, Shepherd FA, Tsao MS. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J Thorac Oncol 3: 527-529, 2008.